18,834 Shares in STERIS plc $STE Bought by Addenda Capital Inc.

Addenda Capital Inc. acquired a new stake in STERIS plc (NYSE:STE) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 18,834 shares of the medical equipment provider’s stock, valued at approximately $4,660,000.

Other large investors also recently modified their holdings of the company. Allworth Financial LP grew its stake in STERIS by 7.3% in the second quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 45 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in STERIS by 34.9% during the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 45 shares during the last quarter. Ashton Thomas Private Wealth LLC lifted its holdings in STERIS by 3.5% during the 1st quarter. Ashton Thomas Private Wealth LLC now owns 1,611 shares of the medical equipment provider’s stock worth $365,000 after buying an additional 54 shares during the last quarter. Balefire LLC grew its position in shares of STERIS by 5.0% in the 3rd quarter. Balefire LLC now owns 1,128 shares of the medical equipment provider’s stock worth $279,000 after acquiring an additional 54 shares in the last quarter. Finally, Berry Wealth Group LP increased its holdings in shares of STERIS by 5.3% in the 2nd quarter. Berry Wealth Group LP now owns 1,251 shares of the medical equipment provider’s stock valued at $300,000 after acquiring an additional 63 shares during the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on STE shares. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and an average target price of $273.50.

STERIS Stock Down 0.1%

STE stock opened at $251.54 on Friday. The firm has a market cap of $24.69 billion, a PE ratio of 36.14 and a beta of 1.01. STERIS plc has a 12 month low of $200.98 and a 12 month high of $268.60. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63. The firm has a 50 day simple moving average of $252.19 and a 200 day simple moving average of $244.05.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same period last year, the company posted $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Equities research analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Tuesday, November 18th were issued a $0.63 dividend. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s dividend payout ratio is currently 36.21%.

Insider Buying and Selling at STERIS

In other news, CEO Daniel A. Carestio sold 159 shares of STERIS stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $241.82, for a total value of $38,449.38. Following the transaction, the chief executive officer owned 51,096 shares of the company’s stock, valued at $12,356,034.72. This trade represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the transaction, the vice president directly owned 5,695 shares of the company’s stock, valued at $1,466,747.25. This represents a 46.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 25,203 shares of company stock valued at $6,624,667. Corporate insiders own 1.07% of the company’s stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.